Pharmacogenetic testing: Time for clinical practice guidelines

Clinical Pharmacology and Therapeutics

Volumn 89, Issue 6, 2011, Pages 924-927

  Amstutz, U ^a,b,c   Carleton, B C ^a,b,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BC CHILDREN S HOSPITAL   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; ATOMOXETINE; CELECOXIB; CEVIMELINE; CLOPIDOGREL; CYTOCHROME P450 2D6; DIAZEPAM; DRUG METABOLITE; DRUG METABOLIZING ENZYME; ENDOXIFEN; ESOMEPRAZOLE; FLUOXETINE; NELFINAVIR; OMEPRAZOLE; PANTOPRAZOLE; PARACETAMOL; PAROXETINE; RABEPRAZOLE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; TERBINAFINE; TIMOLOL MALEATE; TIOTROPIUM BROMIDE; TOLTERODINE; TRAMADOL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE; VORICONAZOLE; WARFARIN;

ARTICLE; BREAST CANCER; CLINICAL DECISION MAKING; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG LABELING; DRUG METABOLISM; DRUG SCREENING; ENZYME ACTIVITY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; EVIDENCE BASED PRACTICE; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HEREDITY; HETEROZYGOTE; HUMAN; HUMAN GENOME; PHARMACOGENETICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT;

EID: 85027935630     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.18     Document Type: Article

References (26)

1. Pirmohamed, M. Acceptance of biomarker-based tests for application in clinical practice: criteria and obstacles. Clin. Pharmacol. Ther. 88, 862-866 (2010).
2. Relling, M.V., Altman, R.B., Goetz, M.P. & Evans, W.E. Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism. Lancet Oncol. 11, 507-509 (2010).
3. Green, M.J. & Botkin, J.R. "Genetic exceptionalism" in medicine: clarifying the diferences between genetic and nongenetic tests. Ann. Intern. Med. 138, 571-575 (2003). (Pubitemid 38124678)
4. Osborne, C.K. Tamoxifen in the treatment of breast cancer. N. Engl. J. Med. 339, 1609-1618 (1998). (Pubitemid 28536137)
5. Desta, Z., Ward, B.A., Soukhova, N.V. & Flockhart, D.A. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J. Pharmacol. Exp. Ther. 310, 1062-1075 (2004). (Pubitemid 39108928)
6. Jin, Y. et al. CYP2D6 genotype, Antidepressant use, And tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl. Cancer Inst. 97, 30-39 (2005).
7. Kelly, C.M. et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 340, C693 (2010).
8. Schroth, W. et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302, 1429-1436 (2009).
9. Kiyotani, K. et al. Signifcant efect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J. Clin. Oncol. 28, 1287-1293 (2010).
10. Ahern, T.P., Pedersen, L., Cronin-Fenton, D.P., Sørensen, H.T. & Lash, T.L. No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications. Cancer Epidemiol. Biomarkers Prev. 18, 2562-2564 (2009).
11. Lash, T.L. et al. Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram. Br. J. Cancer 99, 616-621 (2008).
12. Seruga, B. & Amir, E. Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis. Breast Cancer Res. Treat. 122, 609-617 (2010).
13. Henry, N.L., Stearns, V., Flockhart, D.A., Hayes, D.F. & Riba, M. Drug interactions and pharmacogenomics in the treatment of breast cancer and depression. Am. J. Psychiatry 165, 1251-1255 (2008).
14. Burstein, H.J. et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J. Clin. Oncol. 28, 3784-3796 (2010).
15. Joerger, M. & Thürlimann, B. Update of the BIG 1-98 Trial: where do we stand? Breast 18 (suppl. 3), S78-S82 (2009).
16. Teutsch, S.M. et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet. Med. 11, 3-14 (2009).
17. EGAPP Working Group. Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? Genet. Med. 11, 15-20 (2009).
18. EGAPP Working Group. Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors. Genet. Med. 9, 819-825 (2007).
19. Swen, J.J. et al. Pharmacogenetics: from bench to byte. Clin. Pharmacol. Ther. 83, 781-787 (2008). (Pubitemid 351556025)
20. Mallal, S. et al. HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358, 568-579 (2008).
21. Thervet, E. et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin. Pharmacol. Ther. 87, 721-726 (2010).
22. Epstein, R.S. et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Efectiveness study). J. Am. Coll. Cardiol. 55, 2804-2812 (2010).
23. Lesko, L.J., Zineh, I. & Huang, S.M. What is clinical utility and why should we care? Clin. Pharmacol. Ther. 88, 729-733 (2010).
24. Ansell, J., Hirsh, J., Hylek, E., Jacobson, A., Crowther, M. & Palareti, G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133, 160S-198S (2008). (Pubitemid 351892967)
25. U.S. Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. (2009). Accessed 8 November 2010.
26. Anstey, A.V., Wakelin, S. & Reynolds, N.J. Guidelines for prescribing azathioprine in dermatology. Br. J. Dermatol. 151, 1123-1132 (2004). (Pubitemid 40030158)